Literature DB >> 476649

Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid.

D J Stewart, J A Benvenuto, M Leavens, S W Hall, R S Benjamin, W Plunkett, K B McCredie, M A Burgess, T L Loo.   

Abstract

The antitumor agent 3-deazauridine (DAU) was administered rapidly to four patients before surgical removal of intracerebral tumor. Tumor, adjacent brain tissue, and temporalis muscle were assayed for DAU by high-pressure liquid chromatography. DAU penetrated comparably into tumor, brain, and muscle; in one patient, tissue concentrations were higher than concurrent plasma concentrations. The active metabolite 3-deazauridine 5'-triphosphate was quantitated in one tumor sample and greatly exceeded its Ki for cytidine 5'-triphosphate synthetase. DAU was also present in autopsy brain specimens from two patients treated shortly antemortem. Cerebrospinal fluid concentrations were 22.1 and 59.0%, respectively, of concurrent plasma concentrations during continuous infusion of DAU in two patients. Cerebrospinal fluid concentration was 3.1 microgram/ml 2 hr after a 30-min infusion of 1.5 g of drug per sq m and fell to 1.9 microgram/ml at 16 hr. Thus, DAU is capable of penetrating into intracerebral tumor, brain, and cerebrospinal fluid and is worthy of investigation in the treatment of intracerebral and meningeal neoplasms.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476649

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.

Authors:  W J Moriconi; M Slavik; S Taylor
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

Review 3.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Human central nervous system pharmacology of pentamethylmelamine and its metabolites.

Authors:  D J Stewart; J A Benvenuto; M Leavens; R G Smith; F Cabanillas; R S Benjamin; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

Review 5.  The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.

Authors:  J C Buckner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

6.  Concentration of vinblastine in human intracerebral tumor and other tissues.

Authors:  D J Stewart; K Lu; R S Benjamin; M E Leavens; M Luna; H Y Yap; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

7.  Cisplatin plus cytosine arabinoside in adults with malignant gliomas.

Authors:  D J Stewart; M T Richard; B Benoit; H Hugenholtz; N Russell; J Dennery; E Peterson; Z Grahovac; G Belanger; S Aitkens
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

8.  Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J Dennery; D Nundy; J Prior; V Montpetit; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

9.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J M Dennery; R Belanger; J Gerin-Lajoie; V Montpetit; D Nundy; J Prior; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

10.  Human central nervous system and plasma pharmacology of mitoxantrone.

Authors:  R M Green; D J Stewart; H Hugenholtz; M T Richard; M Thibault; V Montpetit
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.